Invivyd, Inc. (NASDAQ:IVVD) Director Sells $30,718.73 in Stock

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 65,359 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $0.47, for a total transaction of $30,718.73. Following the sale, the director now directly owns 4,012,320 shares of the company’s stock, valued at $1,885,790.40. This represents a 1.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Terrance Mcguire also recently made the following trade(s):

• On Wednesday, December 11th, Terrance Mcguire sold 160,400 shares of Invivyd stock. The shares were sold at an average price of $0.59, for a total value of $94,636.00.
• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The stock was sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Trading Down 17.6 %

IVVD stock traded down $0.10 during trading on Monday, reaching $0.45. The stock had a trading volume of 1,228,420 shares, compared to its average volume of 651,886. The firm has a fifty day moving average price of $0.82 and a 200 day moving average price of $1.05. The company has a market capitalization of $53.89 million, a P/E ratio of -0.23 and a beta of 0.53. Invivyd, Inc. has a 1-year low of $0.45 and a 1-year high of $5.20.

Analysts Set New Price Targets

A number of research firms recently issued reports on IVVD. Morgan Stanley dropped their target price on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. HC Wainwright cut their price objective on Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $9.00 target price on shares of Invivyd in a research note on Thursday, November 21st. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $7.89.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of IVVD. State Street Corp grew its stake in Invivyd by 3.7% during the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after purchasing an additional 35,904 shares in the last quarter. Marshall Wace LLP grew its position in shares of Invivyd by 4.2% during the second quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after buying an additional 31,992 shares in the last quarter. Acadian Asset Management LLC increased its stake in shares of Invivyd by 232.0% in the second quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after buying an additional 474,301 shares during the last quarter. Duquesne Family Office LLC acquired a new stake in Invivyd in the second quarter valued at $629,000. Finally, Renaissance Technologies LLC bought a new position in Invivyd during the 2nd quarter valued at $421,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.